Fundamental Analysis of Ligand Pharmaceuticals Incorp. - Growth / Value Index
LGND - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.0209
Book Value in last 3 years is trending up
Tsr Value Index - Very Poor Score of 15.62
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 16.25 | 92.72 | 133.34 % | |
| Price to Book | 2.97 | 2.18 | -99.91 % | -7.75 |
| Price to Sales | 12.89 | 9.95 | 34.50 % | |
| Enterprise Value to EBITDA Multiple | -220.56 | 27.32 | 68.21 % |
LGND - Profitability Highlights
Profitability Analysis
Piotroski F Score - Excellent Value of 8.0
Earning Yield of 6.21 %
Net profit has jumped from negative to positive
Excellent QoQ /QoQ FY EPS growth
Company Earning excess return
During the past twelve months, the company has given a strong Net Margin of 79.30%
Steady Growth in EPS for last four quarters
Good Return on Equity of 17.40% is achieved by the company
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 17.40 | 2.35 | 100.27 % | 475.33 |
| Return On Asset | 15.29 | 1.98 | 100.29 % | -84.04 |
| Net Profit Margin | 79.30 | 10.73 | 503.48 % | 278.07 |
| Operating Profit Margin | -1.18 | -4.51 | -391.13 % | 9.65 |
| EBITDA Margin | -5.84 | 35.87 | -21.21 % | 9.65 |
Highlights
| Market Cap | 1545.96 M |
| Enterprise Value | 1523.41 M |
| Price/Book TTM | 2.97 |
| Outstanding Share | 17963.70 K |
| Float/ Outstanding Share | 97.88% |
| Dividend Yield | 2.04 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.25 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 8.00 |
| Altman Z Score | 8.52 |
| Sloan Ratio | -0.094 |
| Peter Lynch Fair Value | 0 |
LGND - Growth Highlights
Growth Analysis
Tsr Growth Index - Very Poor Score of 15.14
Annual sales in last 3 years is trending down with Increate in Asset Turnover
Annual sales in last 3 years is trending down
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 118313 K | 21.73 % | 10.24 % |
| Gross Profit | 113164 K | 14.16 % | 17.18 % |
| EBITDA | -6907.00 K | 38.34 % | 188.98 % |
| Net Profit | 93825.00 K | 415.79 % | 373.60 % |
| EPS | 5.29 | 399.98 % | NA |
LGND - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 95.00
Altman Z Score of 8.46 suggests good Stability
Debt to equity ratio has decreased and is lowest in last five years
Cash ratio of 10.15
Company financial liquidity has improved
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0006 | -51.12 % | 0.055 |
| Cash Ratio | 10.15 | 373.29 % | |
| Quick Ratio | 12.72 | 402.11 % | -14.36 |
| Shareholders Equity | 84.14 | 7.40 % | |
| Debt to EBITDA | 0.0074 | 92893.72 % |
Historical Valuation Ratios of Ligand Pharmaceuticals Incorp.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Ligand Pharmaceuticals Incorp.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Ligand Pharmaceuticals Incorp.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Ligand Pharmaceuticals Incorp.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)